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Abstract
Background: Statins may prevent recurrent ischemic events after ischemic stroke. Determining which statin to use
remains controversial. We aimed to summarize the evidence for the use of statins in secondary prevention for
patients with ischemic stroke by comparing benefits and harms of various statins.
Methods: We searched for randomized controlled trials (RCTs) assessing statins in patients with ischemic stroke or
transient ischemic attack (TIA) in MEDLINE, EMBASE, and CENTRAL up to July 2017. Two authors extracted data and
appraised risks of bias. We performed pairwise meta-analyses and trial sequential analyses (TSA) to compare statins
versus placebo/no statin, and network meta-analyses using frequentist random-effects models to compare statins
through indirect evidence. We used GRADE to rate the overall certainty of evidence. Primary outcomes were
all-cause mortality and all strokes. Secondary outcomes were different types of strokes, cardiovascular events,
and adverse events.
Results: We identified nine trials (10,741 patients). No head-to-head RCTs were found. The median follow-up
period was 2.5 years. Statins did not seem to modify all stroke and all-cause mortality outcomes; they were
associated with a decreased risk of ischemic stroke (odds ratio, OR, 0.81 [95% CI, 0.70 to 0.93]; absolute risk
difference, ARD, − 1.6% [95% CI, − 2.6 to − 0.6%]), ischemic stroke or TIA (OR, 0.75 [95% CI, 0.64 to 0.87]; ARD,
− 4.2% [95% CI, − 6.2 to − 2.1%]), and cardiovascular event (OR, 0.75 [95% CI, 0.69 to 0.83]; ARD, − 5.4% [95%
CI, − 6.8 to − 3.6%]), and did not seem to modify rhabdomyolysis, myalgia, or rise in creatine kinase. In the
comparison of different statins, moderate- to high-quality evidence indicated that differences between
pharmaceutical products seemed modest, with high doses (e.g., atorvastatin 80 mg/day and simvastatin 40
mg/day) associated with the greatest benefits. TSA excluded random error as a cause of the findings for
ischemic stroke and cardiovascular event outcomes. Evidence for increased risk of hemorrhagic stroke was
sensitive to the exclusion of the SPARCL trial.
Conclusions: Evidence strongly suggests that statins are associated with a reduction in the absolute risk of
ischemic strokes and cardiovascular events. Differences in effects among statins were modest, signaling
potential therapeutic equivalence.
Trial registration: PROSPERO CRD42018079112
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Background
Stroke is the second most common cause of death in
industrialized countries and the leading cause of per-
manent acquired disability [1, 2]. Although a transient
ischemic attack (TIA) does not leave any impairment,
affected individuals are at a high risk for future ische-
mic events, particularly in the days and weeks imme-
diately following symptom resolution [3]. On average,
the annual risk of future ischemic stroke after an ini-
tial stroke or TIA is 3 to 5% [4]. Patients with ische-
mic stroke or TIA are also at a higher risk for
subsequent myocardial infarction and death from vas-
cular causes [4–6].
Since the risk of ischemic stroke is higher in the
early period after the acute event, prompt initiation
of tailored prevention strategies is essential [7]. It
has been estimated that at least 80% of recurrent
ischemic events in patients with previous ischemic
stroke may be prevented through the use of a
comprehensive approach that includes dietary modi-
fication, exercise, antiplatelet/anticoagulant therapy,
effective strategies for treatment of hypertension,
and statins [8].
Historically, the role of statin therapy in the preven-
tion of cardiovascular disease has been well received by
the medical and scientific communities, with numerous
guidelines promoting their use. Specifically, the 2013
ACC/AHA guideline recommends the use of statins to
reduce the risk of stroke and cardiovascular events in
patients with ischemic stroke or TIA presumed to be of
atherosclerotic origin [6]. Possible adverse events that
have been associated with statin therapy are myopathy
and hemorrhagic stroke [5, 6, 9].
Despite the widespread use of statins, however, the
relative safety and efficacy of different statin drugs have
not been clearly defined. In fact, no head-to-head trial
has directly addressed the effectiveness of these therap-
ies or has clearly defined the choice of a specific statin,
dose (low, moderate, or high), and target (all ischemic
stroke and TIA or non-cardioembolic only or high LDL
cholesterol only) [5, 6, 9].
A more accurate understanding of the effectiveness
and safety of different statins is required to make
appropriate drug choices, both at an individual and
public health level, informing drug prescribing and
procurement. In this network meta-analysis, we aim
to summarize the current evidence for statin use in
secondary prevention of patients with ischemic
stroke or TIA by estimating the relative efficacy and
safety of various statins and providing a final ranking
of the different molecules. Our results may inform
clinicians in their daily practice as well as scientific
societies and agencies developing best practice
guidelines.
Methods
Protocol and registration
The systematic review protocol was developed using
guidance from the Preferred Reporting Items for Sys-
tematic Review and Meta-analysis Protocols (PRIS-
MA-P) statement [10]. We addressed all 17 items within
the PRISMA-P checklist and registered the review in
PROSPERO (CRD42018079112) [11]. We used the
PRISMA-network meta-analysis extension to report the
results [12].
Search strategy and selection criteria
We conducted a systematic review and network
meta-analysis. We searched MEDLINE, EMBASE, and the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) electronic databases from January 2008 to July
2017, with no language restrictions. Search terms included
extensive controlled vocabulary (MeSH and EMTREE) and
keywords, including the names of statins along with differ-
ing terms for stroke and cerebrovascular disease in various
combinations. Details on the search strategies can be found
on PROSPERO (https://www.crd.york.ac.uk/prospero/dis-
play_record.php?RecordID=79112). Studies published be-
fore January 2008 were retrieved from two Cochrane
reviews featuring similar PICOs and a broader inclu-
sion criteria of studies [13, 14]. We did not formally
search for additional unpublished or ongoing studies
as we did not identify additional studies relevant to
our review question during a preliminary check on
ClinicalTrials.gov (http://www.clinicaltrial.gov/) and
the International Clinical Trials Registry Platform
(ICTRP) (http://apps.who.int/trialsearch/).
Eligibility criteria
We included randomized controlled trials (RCTs) com-
paring any single statin at any dose with either a control
(placebo/no statin) or another active statin for secondary
prevention in adults (≥18 years old, both sexes) diag-
nosed with ischemic stroke or TIA in which hemorrhage
had been excluded by neuroimaging. We included all
settings of care (e.g., acute or nursing homes, hospitals
or ambulatory, primary or secondary, inpatients or out-
patients), as well as both acute and delayed treatments.
RCTs comparing the effect of different doses of the same
statin were excluded, except those that included another
eligible comparator. We assumed that medications were
“jointly randomizable” across patients included in the
trials. In other words, a patient could have been, in
principle, randomized to any of the alternative treatment
options; it is, therefore, possible to imagine that a single
randomized trial could have been designed to compare
all of these treatments (transitivity assumption) [15]. We
excluded non-English-language study reports.
Tramacere et al. BMC Medicine           (2019) 17:67 Page 2 of 12
Two authors independently selected the studies,
reviewed the main reports and supplementary materials,
extracted relevant information from the included trials,
and assessed the risk of bias. Any discrepancies were re-
solved by consensus and arbitration by a third author.
Outcomes
Primary outcomes were all-cause mortality and the pro-
portion of patients who developed a stroke after statin
use, irrespective of its type (ischemic or hemorrhagic)
and severity. Secondary outcomes included the propor-
tion of patients who developed an ischemic stroke in
which hemorrhage had been excluded by imaging or
autopsy; an ischemic stroke or TIA irrespective of sever-
ity; a hemorrhagic stroke, defined as an acute extravasa-
tion of blood into the brain parenchyma that excludes
subarachnoid hemorrhage, subdural hematoma, and epi-
dural hematoma [16]; a cardiovascular event defined as
any sudden death, fatal or non-fatal acute coronary syn-
drome, stroke, intracranial hemorrhage, or pulmonary
embolism; and rhabdomyolysis, myalgia, or rise in creat-
ine kinase (CK). For all analyses, we recorded the out-
comes at the longest available follow-up.
We used network plots to describe the network
geometry [17].
Risk of bias assessment and certainty of evidence
We evaluated the risk of bias for each included study
using the criteria of The Cochrane Collaboration [18].
The following domains of bias were considered: selec-
tion (random sequence generation, allocation conceal-
ment), performance, detection (blinding of participants
and personnel, and of outcome assessment), attrition
(incomplete outcome data), selective outcome reporting,
and the role of the sponsor in the authorship of the
study report or in data management or analysis. We ex-
plicitly judged the risk of bias in each criterion as “low,”
“high,” or “unclear.” We considered the blinding of par-
ticipants, personnel, and outcome assessment separately
for objective outcomes (e.g., mortality) and subjective
outcomes (myalgia). We evaluated incomplete outcome
data as having a low risk of bias when the numbers and
reasons for dropouts were balanced (i.e., in the absence
of a significant difference) between arms. Our assess-
ment of methodological quality included published trial
protocols, when available. To summarize the quality of
the evidence, we considered allocation concealment,
blinding of outcome assessment, and incomplete out-
come data; we classified each study as having a low risk
of bias when all three criteria were evaluated at a low
risk of bias; a high risk of bias when at least one criter-
ion was at high risk of bias; and a moderate risk of bias
in the remaining cases. This appraisal was conducted by
pairs of independent reviewers, with conflicts resolved
by a third reviewer. We examined the overall certainty
of the evidence for primary and secondary outcomes
using the Grading of Recommendation, Assessment, De-
velopment and Evaluation (GRADE) framework method-
ology [19]. We revised and assessed each GRADE item
(study limitations, inconsistency, indirectness, impreci-
sion, and publication bias) considering issues related
specifically to the network meta-analysis methodology:
the presence of indirect comparisons, the influence of
each direct piece to the network meta-analysis evidence,
and the role of the consistency assumption for the valid-
ity of the estimates [20].
Statistical analyses
We estimated treatment effects from each study using
the odds ratio (OR) with 95% confidence intervals (95%
CIs). For all outcomes with at least two studies, we per-
formed standard pairwise meta-analyses of any statin
versus placebo/no statin with a random-effects model.
We compared different statins through network
meta-analyses performed under a frequentist framework
using a random-effects model. Results of network
meta-analyses were presented in league tables and forest
plots. For each outcome, we estimated the probability of
each treatment included in the network to be the best
among all treatments by using the surface under the cu-
mulative ranking curve area (SUCRA) [21]. We pre-
sented the results from pairwise meta-analyses and the
network meta-analysis as summary relative effect sizes.
We reported absolute risk difference (ARD) estimates,
calculated using as baseline the proportion of patients
with an event in the control arm of the included studies,
and applying the OR estimated in the meta-analysis to
compute the absolute difference between the interven-
tion and control arms. In the standard pairwise
meta-analyses, we assessed clinical heterogeneity by
comparing the data on potential effect modifiers, and
determined the presence of statistical heterogeneity by
visual inspection of the forest plots and calculation of
the I2 statistic [22]. We assumed a common estimate for
the heterogeneity variance across treatment comparisons
in the network meta-analysis. We compared the distri-
bution of potential effect modifiers across different pair-
wise comparisons to assess transitivity across treatment
comparisons. We checked for the presence of statistical
heterogeneity in the entire network by considering the
magnitude of the common heterogeneity parameter [23].
As only direct evidence was available, we were not able
to assess incoherence (defined as the statistical disagree-
ment between direct and indirect evidence) within each
network. We performed subgroup analyses of any statin
versus placebo/no statin considering the following po-
tential sources of heterogeneity (effect modifiers): stroke
subtypes at inclusion, treatment dose intensity as defined
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in the 2013 ACC/AHA Guideline [24], and time from
the first ischemic event to randomization. We performed
sensitivity analyses of any statin versus placebo/no statin
for each primary and secondary outcome, including only
trials that were classified as having a low risk of bias. In
order to control for the risks of type I and type II errors
due to sparse data and repetitive testing of accumulating
data, a trial sequential analysis of any statin versus pla-
cebo/no statin was performed for each primary and sec-
ondary outcome with at least two studies. Each trial
sequential analysis provided the required information
size for a meta-analysis and calculated the adjusted stat-
istical thresholds for benefits, harms, or futility before
the required information size was reached. The following
assumptions were used: the proportion of participants in
the control group with events; a relative risk reduction
or an increase of 10% for primary outcomes, and of both
10% and 20% for secondary outcomes; a type I error of
5%; a type II error of 20%; and the observed diversity of
the meta-analysis [25–28].
Finally, we performed a post hoc sensitivity analysis,
which was prompted by external reviewer comments:
we used a leave-one-out meta-analysis to assess the
independent influence of each study on the summary
estimate [29].
Results
A total of 2975 citations were identified by the search,
and 58 potentially eligible articles were retrieved in
full-text (Fig. 1). Overall, ten trials were included in the
review [30–39]. With the exception of Plehn 1999 [30],
which did not report separate results for patients with
ischemic stroke at inclusion, the remaining nine studies
presented data suitable for meta-analysis (n = 10,741 pa-
tients). Table 1 summarizes the characteristics of in-
cluded studies. In three trials, the lipid-lowering drug
was compared to no statin [35–37], while the remaining
trials compared the drug to placebo [30–34, 38, 39].
Atorvastatin was studied in a single large trial [33], while
simvastatin was studied in four trials [32, 34, 35, 39],
pravastatin in three [30, 31, 36], and rosuvastatin in two
[37, 38]. Across studies, most patients were randomized
to atorvastatin (n = 2365), followed by simvastatin (n =
1870), pravastatin (n = 1060), and rosuvastatin (n = 167).
Based on dose intensity defined in the 2013 ACC/AHA
Guideline [24], one out of ten trials investigated statins
Fig. 1 Study selection
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at a low-intensity dose (i.e., pravastatin 10mg/day) [36],
seven at a moderate-intensity dose (i.e., pravastatin 40
mg/day, rosuvastatin 5mg/day, or simvastatin 40mg/
day) [30–32, 34, 35, 37, 39], and two at a high-intensity
dose (i.e., atorvastatin 80mg/day or rosuvastatin 20 mg/
day) [33, 38]. Among the eight RCTs reporting informa-
tion on the time from the first ischemic event to
randomization, five studies randomized patients within
1 week of the first event [34, 35, 37–39], and three stud-
ies at least 1 month after the first event [32, 33, 36]. Six
of ten RCTs randomized patients with both cardioem-
bolic and non-cardioembolic ischemic stroke [30–32, 34,
35, 39], and four RCTs randomized only patients with a
non-cardioembolic ischemic stroke at inclusion [33, 36–
38]. When the information was available, patients were
more frequently men (54–96%), with the exception of
two RCTs in which men were 44% and 48% of the study
population [34, 35]. The mean range of age was 63–74
years. All five RCTs that had available information ran-
domized patients with mild to moderate severity stroke
at inclusion (mean National Institutes of Health Stroke
Scale, NIHSS, at baseline lower than 15) [34, 35, 37–39].
The median follow-up period was 2.5 years (range, 5
days–6 years), and four RCTs [31–33, 36] had a
follow-up period of at least 4 years.
Overall, one (10%) trial was rated as high risk of bias,
three (30%) trials as moderate, and six (60%) trials as
low (Fig. 2). By using GRADE, we rated the quality of
evidence as high for ischemic stroke, ischemic stroke or
TIA, and cardiovascular event; moderate for all strokes;
and low for all-cause mortality, hemorrhagic stroke, and
rhabdomyolysis, myalgia, or rise in CK outcomes.
Figure 3 shows the network geometry for each primary
and secondary outcome. Figure 4 shows the estimates of
primary and secondary outcomes of any statin against
placebo/no statin from the standard meta-analysis, and
of each statin against placebo/no statin from the net-
work meta-analysis, with the corresponding ranking
probability (SUCRA) and quality of evidence (GRADE)
for each outcome. Additional file 1: Tables S1-S6 shows
the network meta-analysis estimates of primary and sec-
ondary outcomes for each comparison between different
statins and placebo/no statin.
Seven RCTs, comprising 10,398 patients, addressed all
stroke outcomes comparing a statin versus placebo/no
statin. Moderate-quality evidence indicated that 10.4%
patients taking a statin experienced a stroke (ischemic
or hemorrhagic) compared with 11.3% patients taking
placebo/no statin (OR, 0.90 [95% CI, 0.80 to 1.02]; ARD,
− 1.0% [95% CI, − 2.1 to 0.2%]). By comparing different
statins, high-quality evidence indicated that atorvastatin
80mg/day was associated with the greatest benefit (one
RCT comprising 4731 patients; OR, 0.83 [95% CI, 0.70 to
0.99]; SUCRA, 89%; ARD, − 1.7% [95% CI, − 3.1 to − 0.1%]).
Five RCTs, comprising 6910 patients, addressed
all-cause mortality outcome comparing a statin versus
placebo/no statin. Low-quality evidence indicated that
7.9% of patients taking a statin for up to 5 years died
compared with 7.7% patients taking placebo/no statin
(OR, 1.04 [95% CI, 0.87 to 1.25]; ARD, 0.3% [95% CI,
− 0.9 to 1.7%]). Uncertain estimates based on low- to
very low-quality evidence prevented us from determining
a reliable treatment hierarchy among different statins.
Eight RCTs, comprising 10,394 patients, addressed the
ischemic stroke outcome comparing a statin versus pla-
cebo/no statin. High-quality evidence indicated that
7.6% of patients taking a statin experienced an ischemic
stroke compared with 9.3% of patients taking placebo/no
statin (OR, 0.81 [95% CI, 0.70 to 0.93]; ARD, − 1.6%
[95% CI, − 2.6 to − 0.6%]). By comparing different sta-
tins, moderate- to high-quality evidence indicated that
Fig. 2 Risk of bias of the included studies
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atorvastatin 80 mg/day (one RCT comprising 4731 pa-
tients; OR, 0.78 [95% CI, 0.64 to 0.94]; SUCRA, 68%;
ARD, − 1.9 [95% CI, − 3.1 to − 0.5%]) and simvastatin 40
mg/day (four RCT comprising 3747 patients; OR, 0.83
[95% CI, 0.64 to 1.07]; SUCRA, 55%; ARD, − 1.5% [95%
CI, − 3.1 to 0.6%]) were associated with the greatest
benefits.
One RCT, comprising 4731 patients, addressed the is-
chemic stroke or TIA outcome comparing atorvastatin
80mg/day versus placebo. High-quality evidence indi-
cated that 15.9% of patients taking atorvastatin 80mg/
day experienced an ischemic stroke or TIA compared
with 20.1% of patients taking placebo (OR, 0.75 [95% CI,
0.64 to 0.87]; ARD, − 4.2% [95% CI, − 6.2 to − 2.1%]).
Six RCTs, comprising 9976 patients, addressed the
hemorrhagic stroke outcome comparing a statin versus
placebo/no statin. Evidence indicated that 1.8% of pa-
tients taking a statin experienced a hemorrhagic stroke
compared with 1.2% of patients taking placebo/no statin
(OR, 1.54 [95% CI, 1.10 to 2.15]; ARD, 0.6% [95% CI, 0.1
to 1.3%]). A post hoc influence (leave-one-out) analysis
showed that results were influenced by the largest trial.
The meta-analysis of hemorrhagic strokes was sensitive
to the exclusion of the Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) trial, and
when excluded, the overall estimate moved towards no
difference (OR, 1.35 [95% CI, 0.78 to 2.33]). We down-
graded the evidence to low due to inconsistency and im-
precision in the absolute risks for hemorrhagic stroke.
Thus, the evidence suggests that the true role of statins
in causing hemorrhagic stroke could be different from
that observed in our overall estimate. The same caveat
applies to single-agent analyses. Low-quality evidence in-
dicated that atorvastatin 80 mg/day (one RCT compris-
ing 4731 patients; OR, 1.68 [95% CI, 1.09 to 2.60];
SUCRA, 21%; ARD, 0.8% [95% CI, 0.1% to 1.8%]) and
simvastatin 40mg/day (four RCT comprising 3667 pa-
tients; OR, 1.69 [95% CI, 0.85–3.34]; SUCRA, 24%; ARD,
0.8% [95% CI, 0.2% to 2.6%]) were associated with po-
tential harms.
Six RCTs, comprising 10,192 patients, addressed the
cardiovascular event outcome comparing a statin versus
placebo/no statin. High-quality evidence indicated that
22.8% patients taking a statin experienced a cardiovascular
Fig. 3 Network plots of evidence for primary and secondary outcomes: each line links the treatments that have been directly compared in
studies. The thickness of the line is proportional to the precision of each direct estimate, and the width of each circle is proportional to the
number of studies included in the treatment. The number of studies per comparison is reported next to each line, and the number of patients
included in each treatment is reported in the bracket below the treatment name
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event compared with 28.0% patients taking placebo/no
statin (OR, 0.75 [95% CI, 0.69 to 0.83]; ARD, − 5.4% [95%
CI, − 6.8 to − 3.6%]). By comparing different statins, mod-
erate- to high-quality evidence indicated that atorvastatin
80mg/day (one RCT comprising 4731 patients; OR, 0.71
[95% CI, 0.62 to 0.80]; SUCRA, 91%; ARD, − 6.4% [95%
CI, − 8.6 to − 4.3%]), simvastatin 40mg/day (three RCT
comprising 3569 patients; OR, 0.77 [95% CI, 0.67 to 0.90];
SUCRA, 70%; ARD, − 5.0% [95% CI, − 7.3 to − 2.1%]), and
pravastatin 10mg/day (one RCT comprising 1578 pa-
tients; OR, 0.82 [95% CI, 0.66 to 1.02]; SUCRA, 58%;
ARD, − 3.8% [95% CI, − 7.6 to 4.0%]) were associated with
the greatest benefits.
Three RCTs, comprising 6610 patients, addressed
rhabdomyolysis, myalgia, or a rise in CK as a safety out-
come comparing a statin versus placebo/no statin.
Low-quality evidence indicated that 4.6% of patients tak-
ing a statin experienced rhabdomyolysis, myalgia, or a rise
in CK compared with 4.8% of patients taking a placebo/no
statin (OR, 0.95 [95% CI, 0.75 to 1.19]; ARD, − 0.2% [95%
CI, − 1.2 to 0.9%]). Uncertain estimates based on low- to
very low-quality evidence did not allow us to determine a
reliable treatment hierarchy among different statins.
Heterogeneity estimates for standard pairwise meta-
analysis and network meta-analysis in each outcome were
low (Additional file 1: Tables S1-S10).
For each outcome, subgroup analyses by stroke
subtypes at inclusion (i.e., studies including both
cardioembolic and non-cardioembolic ischemic strokes
versus those including non-cardioembolic ischemic
strokes only), treatment dose (i.e., studies investigating
statins at low- versus medium- versus high-intensity
dose), and time from the first ischemic event to
randomization (i.e., studies on patients randomized
within 7 days versus beyond 1 month from the first is-
chemic event), as well as a sensitivity analysis including
only trials classified as having a low risk of bias, did not
show any significant difference compared to the overall
analysis (Additional file 1: Tables S7-S10).
Based on a relative risk reduction or increase of 10%, a
trial sequential analysis provided the required informa-
tion size of 23,562 for all strokes (information deficit
13,164), 35,902 for all-cause mortality (information def-
icit 28,992), 29,238 for ischemic stroke (information def-
icit 18,844), and 65,217 for rhabdomyolysis, myalgia, or
rise in CK (information deficit 58,607). The correspond-
ing cumulative Z curves did not cross the trial sequential
monitoring boundaries for benefit, harm, or futility. We
cannot exclude, therefore, the risks of random type II
error since the total sample sizes in the meta-analyses of
these outcomes (from 6610 to 10,398) were considerably
underpowered to identify a difference. The required in-
formation size was not quantifiable for hemorrhagic
stroke due to the large distance between the accrued in-
formation and the required information. Conversely, a
trial sequential analysis on the cardiovascular event
Fig. 4 Forest plot of meta-analysis estimates of any statin against placebo/no statin, and of each treatment against placebo/no statin within the
networks for primary and secondary outcomes with at least two studies, with the corresponding ranking probability (SUCRA) and quality of
evidence (GRADE) for each intervention for each outcome
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outcome showed that the total sample size of 10,192 was
higher than the required information size of 7819 calcu-
lated (information excess 2373); the corresponding cu-
mulative Z curve crossed the trial sequential monitoring
boundary for benefit after the first trial and never
regressed. Accordingly, we can exclude random error as
a cause of the finding for this outcome. Based on a rela-
tive risk reduction or increase of 20% (analyses con-
ducted for secondary outcomes only), the trial sequential
analysis computed a required information size of 6960
for ischemic stroke (information excess 3434), 70,999 for
hemorrhagic stroke (information deficit 61,023), and
17,038 for the rhabdomyolysis, myalgia, or rise in CK
outcome (information deficit 10,428). The corresponding
cumulative Z curves for hemorrhagic stroke and the
rhabdomyolysis, myalgia, or rise in CK outcome did not
cross the trial sequential monitoring boundaries, while
the cumulative Z curve for ischemic stroke outcome
crossed the trial sequential monitoring boundary for
benefit after the first trial and never regressed, together
with a total sample size of 10,394 (i.e., higher than the
required information size of 6960). The required infor-
mation size was not quantifiable for cardiovascular event
as the first information fraction exceeded 100% of the
required information size boundary.
Discussion
In this systematic review, network meta-analysis, and
trial sequential analysis, we found that statins for sec-
ondary prevention in patients with ischemic stroke or
TIA do not seem to modify all stroke and all
cause-mortality outcomes; however, they reduce the rela-
tive risk of recurrent ischemic strokes by almost 20%,
which corresponds to an absolute risk reduction of 1.6%,
and the risk of cardiovascular events by more than 20%,
which corresponds to an absolute risk reduction of 5.4%.
These effects should be considered as clinically relevant
based on our predefined minimal relevant differences
and, by GRADE, are considered to be of high quality.
Data from RCTs were not sufficient to assess if these ef-
fects are larger among patients at high risk, although
guidelines in secondary prevention recommend treat-
ment with statins particularly in patients with high LDL
cholesterol levels to achieve a reduction of at least 50%
through a high-intensity dose [6], based primarily on
data from a secondary analysis of the SPARCL trial [40].
Furthermore, our meta-analysis shows a consistent effect
within different groups of patients at risk by subtype of
stroke, treatment dose, and time from first ischemic
event to randomization. Our results suggest that the use
of statins is safe: the most conservative analysis shows
that statins might be associated with a higher relative
risk of hemorrhagic stroke of about 50%, although only
a minority of patients (less than 2%) would be exposed
to the incremented risk corresponding to an absolute
risk increase of 0.6%. The observed increased risk of
hemorrhagic stroke is principally due to data from the
SPARCL trial [33] in which the integrity of the interven-
tion (statins and co-treatments, such as hypertensive
therapies) was possibly not maintained over time. Thus,
this finding could be an artifact. Results on all strokes,
all-cause mortality, and the rhabdomyolysis, myalgia, or
rise in CK outcome did not show relevant differences in
risk between treated patients and controls, although the
corresponding data were underpowered as shown by the
trial sequential analysis. Finally, we found no differences
among different statins. If any, the difference seems to
be related to very high doses as atorvastatin 80mg/day
and simvastatin 40mg/day were tested in a few trials.
While the effectiveness of statin therapy in preventing
cardiovascular events in patients with prior ischemic
stroke or TIA has been largely uncontested, recent investi-
gations have raised questions as to the accuracy of data
comparing the relative efficacy and safety of different sta-
tin drugs. Bero and colleagues pointed out that RCTs of
head-to-head comparisons of statins with other drugs are
more likely to report results and conclusions in favor of
the product made by the sponsor versus the comparator
drug [41]. The favoritism in study outcomes may be the
consequence of non-equivalent doses or coding and ana-
lysis of outcomes [42]. While nearly 15 different statin
drugs have been developed by pharmaceutical companies
over the years, only a few drugs have dominated the
market, supported by the results of various industry-spon-
sored trials. A 1996 study showing atorvastatin to most
dramatically reduce LDL levels compared with its compet-
itors simvastatin, lovastatin, fluvastatin, and pravastatin
brought atorvastatin to the limelight, causing it to become
one of the highest revenue-generating drugs of all time.
Interestingly, the release of the drug in 1997 coincided
with the US Food and Drug Administration’s approval of
Direct-to-Consumer Pharmaceutical Advertising, which
allowed for the broadcast advertisement of prescription
drugs. These events made atorvastatin the main drug of
choice, even though there is no strong evidence support-
ing large differences among statins in human or animal
studies [43, 44]. The results of our network meta-analysis
and trial sequential analysis caution the preferential use
of a particular statin based on industry-sponsored
studies, as different statin drugs appear to be compar-
able in the secondary prevention of all strokes, ische-
mic strokes, and all-cause mortality.
Even if the clinical effects of statins are similar, they
can differ in other important dimensions such as phar-
macokinetic properties. Statins show different suscepti-
bilities to metabolism by different isoenzymes in the
cytochrome CYP450 family. Drugs or food that inhibit
CYP3A4 (e.g., macrolides, grapefruit) can markedly
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increase the plasma levels of simvastatin and lovastatin
given their low bioavailability, and, to a less extent, that
of atorvastatin, with a consequent increase in risk of
rhabdomyolysis and muscular toxicity [45, 46]. Con-
versely, rosuvastatin and pravastatin do not undergo
substantial metabolism via the CYP450 pathway [47].
The estimates of treatment effect from our study par-
allel that of previous reviews featuring standard pairwise
meta-analyses on the same matter [13, 14, 48, 49], but
are more precise due to our larger quantity of data and
resulting statistical power. Accordingly, our findings,
based on about 2200 additional patients, confirm those
from a Cochrane review on interventions in the manage-
ment of serum lipids for preventing stroke recurrence
published in 2009, which reported a borderline statistical
difference favoring the statin group compared with the
placebo group in stroke recurrence [13]. Our results are
also aligned with those reported in a systematic review
on secondary prevention of non-cardioembolic stroke
published in 2009 [48]. Finally, we confirm the data on
statin use in an acute phase of ischemic stroke and TIA
provided by two previous reviews, which reported no
statistically significant difference in the effect of statins
possibly due to the limited number of studies and conse-
quent lack of power [14, 49].
The findings from this systematic review may be lim-
ited by the fact that we did not search for unpublished
trials. Moreover, analyses were restricted by the amount
of data in the included studies, the absence of
head-to-head trials, and the scarcity of data on patients
at high risk for which little can be concluded about the
benefits and harms of statins. We did not perform a for-
mal cost-effectiveness analysis. Some of the statistical
techniques, despite being sophisticated, did not change
the actual paradigm of the clinical treatment of strokes
with statins. Notwithstanding the above limitations, this
review also features strengths, including the implemen-
tation of a trial sequential analysis methodology to con-
trol the risk of false-positive results in meta-analysis
owing to sparse data and the repetitive analyses of data
[25–28], which adds some certainty to previous findings.
We developed and published a protocol before we
embarked on the review itself, and we conducted
extensive searches of relevant databases. Finally, our
meta-analysis, conducted in a well-defined vulnerable
population, makes an in-depth evaluation of the possible
differences between statins, limiting the role of possible
distortions related to funding or biases. Our study fur-
ther assessed the outcomes for which evidence can be
considered conclusive.
Conclusions
The findings from this network meta-analysis represent
the most comprehensive evidence base to date that can
guide best practice strategies for statin treatment in
adults with a previous stroke or TIA. Statins do not ap-
pear to be better than placebo at preventing all strokes
and all-cause mortality; however, they appear to reduce
the risk of recurrent ischemic strokes and other cardio-
vascular events in patients with a previous stroke or
TIA, with a limited risk of adverse events. The possibil-
ity of potential effect differences between statins cannot
be dismissed given the potential limitations of the meth-
odology, the complexity of patient populations at risk of
stroke recurrence, and the uncertainties that may arise
from the choice of dose or treatment setting. We hope
that these results will assist in shared decision-making
between patients and their clinicians and will inform the
procurement of medicines within national health care
systems.
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